Pharma Focus Asia

Fresenius Kabi Targets Treatment of Certain Seizures with Launch of Generic Lacosamide Injection, USP

Friday, December 16, 2022

Fresenius Kabi announced today the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT®. Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.

“Fresenius Kabi is pleased to provide the clinicians and patients who rely on us with high quality and accessible choices for treating patients with certain seizures,” said John Ducker, president and CEO of Fresenius Kabi USA.

Fresenius Kabi produces Lacosamide Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems. To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit “More in America.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024